

US Patent & Trademark Office

Patent Public Search | Text View

| | |
|----------------------|------------------------------|
| United States Patent | 12384783 |
| Kind Code | B2 |
| Date of Patent | August 12, 2025 |
| Inventor(s) | Wennogle; Lawrence P. et al. |

Salts and crystals

Abstract

The disclosure provides new, stable, pharmaceutically acceptable hydrochloride salt forms of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H - pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.

Inventors: Wennogle; Lawrence P. (Hillsborough, NJ), Li; Peng (New Milford, NJ), Aret; Edwin (Almere, NL)

Applicant: INTRA-CELLULAR THERAPIES, INC. (New York, NY)

Family ID: 65903143

Assignee: INTRA-CELLULAR THERAPIES, INC. (Bedminster, NJ)

Appl. No.: 17/815843

Filed: July 28, 2022

Prior Publication Data

| Document Identifier | Publication Date |
|---------------------|------------------|
| US 20220363682 A1 | Nov. 17, 2022 |

Related U.S. Application Data

division parent-doc US 16649515 US 11440911 WO PCT/US2018/052922 20180926 child-doc US 17815843
us-provisional-application US 62563341 20170926

Publication Classification

Int. Cl.: C07D471/16 (20060101)

U.S. Cl.:

CPC **C07D471/16** (20130101); C07B2200/13 (20130101)

Field of Classification Search

CPC: C07D (471/16)

References Cited

U.S. PATENT DOCUMENTS

| Patent No. | Issued Date | Patentee Name | U.S. Cl. | CPC |
|-------------------|--------------------|----------------------|-----------------|------------|
| 4162318 | 12/1978 | Silvestrini | N/A | N/A |
| 5114976 | 12/1991 | Norden | N/A | N/A |
| 5151419 | 12/1991 | Perenyi et al. | N/A | N/A |
| 6548493 | 12/2002 | Robichaud et al. | N/A | N/A |
| 6552017 | 12/2002 | Robichaud et al. | N/A | N/A |
| 6699852 | 12/2003 | Robichaud et al. | N/A | N/A |
| 6713471 | 12/2003 | Robichaud et al. | N/A | N/A |
| 6759554 | 12/2003 | Buchwald et al. | N/A | N/A |
| 6849619 | 12/2004 | Robichaud et al. | N/A | N/A |
| 7071186 | 12/2005 | Robichaud et al. | N/A | N/A |
| 7081455 | 12/2005 | Robichaud et al. | N/A | N/A |
| 7109339 | 12/2005 | Lee et al. | N/A | N/A |
| 7183282 | 12/2006 | Robichaud et al. | N/A | N/A |
| RE39679 | 12/2006 | Robichaud et al. | N/A | N/A |
| RE39680 | 12/2006 | Robichaud et al. | N/A | N/A |
| 7238690 | 12/2006 | Robichaud et al. | N/A | N/A |
| 7462641 | 12/2007 | Igo et al. | N/A | N/A |
| 7799785 | 12/2009 | Cid-Nunez et al. | N/A | N/A |
| 7998971 | 12/2010 | Barlow et al. | N/A | N/A |
| 8309722 | 12/2011 | Tomesch et al. | N/A | N/A |
| 8598119 | 12/2012 | Mates et al. | N/A | N/A |
| 8648077 | 12/2013 | Tomesch et al. | N/A | N/A |
| 8779139 | 12/2013 | Tomesch et al. | N/A | N/A |
| 8791138 | 12/2013 | Seeman et al. | N/A | N/A |
| 8993572 | 12/2014 | Mates et al. | N/A | N/A |
| 9168258 | 12/2014 | Mates et al. | N/A | N/A |
| 9199995 | 12/2014 | Tomesch et al. | N/A | N/A |
| 9315504 | 12/2015 | Tomesch et al. | N/A | N/A |
| 9371324 | 12/2015 | Mates et al. | N/A | N/A |
| 9428506 | 12/2015 | Mates et al. | N/A | N/A |
| 9586960 | 12/2016 | Tomesch et al. | N/A | N/A |
| 9616061 | 12/2016 | Mates et al. | N/A | N/A |
| 9708322 | 12/2016 | Peng et al. | N/A | N/A |
| 9745300 | 12/2016 | Mates et al. | N/A | N/A |
| 9751883 | 12/2016 | Tomesch et al. | N/A | N/A |
| 9956227 | 12/2017 | Vanover et al. | N/A | N/A |
| 10072010 | 12/2017 | Li et al. | N/A | N/A |

| | | | | |
|----------|---------|------------------|-----|-----|
| 10077267 | 12/2017 | Mates et al. | N/A | N/A |
| 10117867 | 12/2017 | Mates et al. | N/A | N/A |
| 10221176 | 12/2018 | Tomesch et al. | N/A | N/A |
| 10245260 | 12/2018 | Yao et al. | N/A | N/A |
| 10322134 | 12/2018 | Vanover et al. | N/A | N/A |
| 10464938 | 12/2018 | Tomesch et al. | N/A | N/A |
| 10472359 | 12/2018 | Li et al. | N/A | N/A |
| 10597394 | 12/2019 | Mates et al. | N/A | N/A |
| 10597395 | 12/2019 | Tomesch et al. | N/A | N/A |
| 10654854 | 12/2019 | Li et al. | N/A | N/A |
| 10682354 | 12/2019 | Wennogle | N/A | N/A |
| 10688097 | 12/2019 | Yao et al. | N/A | N/A |
| 10695345 | 12/2019 | Li et al. | N/A | N/A |
| 10702522 | 12/2019 | Mates et al. | N/A | N/A |
| 10716786 | 12/2019 | Li et al. | N/A | N/A |
| 10799500 | 12/2019 | Yao et al. | N/A | N/A |
| 10844061 | 12/2019 | Li et al. | N/A | N/A |
| 10899762 | 12/2020 | Mates et al. | N/A | N/A |
| 10906906 | 12/2020 | Li et al. | N/A | N/A |
| 10960009 | 12/2020 | Vanover et al. | N/A | N/A |
| 10960010 | 12/2020 | Vanover et al. | N/A | N/A |
| 10961245 | 12/2020 | Li et al. | N/A | N/A |
| 11014925 | 12/2020 | Li et al. | N/A | N/A |
| 11026951 | 12/2020 | Vanover et al. | N/A | N/A |
| 11052083 | 12/2020 | Li et al. | N/A | N/A |
| 11053245 | 12/2020 | Mates et al. | N/A | N/A |
| 11066407 | 12/2020 | Tomesch et al. | N/A | N/A |
| 11096944 | 12/2020 | Yao et al. | N/A | N/A |
| 11124514 | 12/2020 | Mates et al. | N/A | N/A |
| RE48825 | 12/2020 | Tomesch et al. | N/A | N/A |
| RE48839 | 12/2020 | Mates et al. | N/A | N/A |
| 11311536 | 12/2021 | Li et al. | N/A | N/A |
| 11331316 | 12/2021 | Li et al. | N/A | N/A |
| 11332469 | 12/2021 | Mittelman et al. | N/A | N/A |
| 11376249 | 12/2021 | Li et al. | N/A | N/A |
| 11407751 | 12/2021 | Tomesch et al. | N/A | N/A |
| 11427587 | 12/2021 | Li et al. | N/A | N/A |
| 11440911 | 12/2021 | Wennogle et al. | N/A | N/A |
| 11453670 | 12/2021 | Li et al. | N/A | N/A |
| 11560382 | 12/2022 | Mates et al. | N/A | N/A |
| 11680065 | 12/2022 | Li et al. | N/A | N/A |
| 11723909 | 12/2022 | Yao et al. | N/A | N/A |
| 11806347 | 12/2022 | Li et al. | N/A | N/A |
| 11806348 | 12/2022 | Li et al. | N/A | N/A |
| 11957791 | 12/2023 | Li et al. | N/A | N/A |
| 11958852 | 12/2023 | Mates et al. | N/A | N/A |
| 11980617 | 12/2023 | Snyder et al. | N/A | N/A |
| 12070459 | 12/2023 | Li et al. | N/A | N/A |
| 12090155 | 12/2023 | Mates et al. | N/A | N/A |
| 12144808 | 12/2023 | Li et al. | N/A | N/A |

| | | | | |
|--------------|---------|------------------|-----|-----|
| 2010/0204470 | 12/2009 | Wieser et al. | N/A | N/A |
| 2015/0072964 | 12/2014 | Mates et al. | N/A | N/A |
| 2015/0079172 | 12/2014 | Mates et al. | N/A | N/A |
| 2015/0080404 | 12/2014 | Mates et al. | N/A | N/A |
| 2018/0271862 | 12/2017 | Li et al. | N/A | N/A |
| 2019/0112309 | 12/2018 | Li et al. | N/A | N/A |
| 2019/0112310 | 12/2018 | Li et al. | N/A | N/A |
| 2019/0211015 | 12/2018 | Mittelman et al. | N/A | N/A |
| 2019/0231780 | 12/2018 | Yao et al. | N/A | N/A |
| 2020/0102309 | 12/2019 | Li et al. | N/A | N/A |
| 2020/0148683 | 12/2019 | Peddy et al. | N/A | N/A |
| 2020/0157100 | 12/2019 | Li | N/A | N/A |
| 2020/0392135 | 12/2019 | Wennogle et al. | N/A | N/A |
| 2020/0407362 | 12/2019 | Mates et al. | N/A | N/A |
| 2021/0002280 | 12/2020 | Mates et al. | N/A | N/A |
| 2021/0008065 | 12/2020 | Li et al. | N/A | N/A |
| 2021/0009592 | 12/2020 | Li et al. | N/A | N/A |
| 2021/0315891 | 12/2020 | Li et al. | N/A | N/A |
| 2022/0024924 | 12/2021 | Janton et al. | N/A | N/A |
| 2022/0041600 | 12/2021 | Li | N/A | N/A |
| 2022/0056031 | 12/2021 | Li et al. | N/A | N/A |
| 2022/0362241 | 12/2021 | Davis et al. | N/A | N/A |
| 2023/0271962 | 12/2022 | Li et al. | N/A | N/A |
| 2023/0339951 | 12/2022 | Li et al. | N/A | N/A |
| 2023/0346787 | 12/2022 | Yao et al. | N/A | N/A |
| 2023/0355616 | 12/2022 | Mates et al. | N/A | N/A |
| 2023/0372336 | 12/2022 | Dutheil et al. | N/A | N/A |
| 2024/0000781 | 12/2023 | Li | N/A | N/A |
| 2024/0115565 | 12/2023 | Li | N/A | N/A |
| 2024/0279228 | 12/2023 | Li | N/A | N/A |
| 2024/0307386 | 12/2023 | Snyder et al. | N/A | N/A |

FOREIGN PATENT DOCUMENTS

| Patent No. | Application Date | Country | CPC |
|-------------------|-------------------------|----------------|------------|
| 109867674 | 12/2018 | CN | N/A |
| WO 2009/017836 | 12/2008 | WO | N/A |
| WO 2018/106916 | 12/2017 | WO | N/A |
| WO 2019/102240 | 12/2018 | WO | N/A |
| WO 2020/182978 | 12/2019 | WO | N/A |
| WO 2022/199708 | 12/2021 | WO | N/A |

OTHER PUBLICATIONS

Longo et al., “The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review,” Brain Sci. Nov. 26, 2023;13(12):1641. (Year: 2023). cited by examiner

Suppes et al., “Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial,” Bipolar Disorders, 2023;25:478-488. (Year: 2023). cited by examiner

Vanover et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,” Neuropsychopharmacology Jun. 11, 2018. (Year: 2018). cited by examiner

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial With ITI-007 in Patients With Sleep Maintenance Insomnia | Intra-Cellular Therapies Inc. (date accessed Jan. 14, 2025), press release dated Jan. 13, 2009 for treating insomnia with Iti-007. (Year: 2025). cited by examiner

Poster Presentations Monday Jul. 23, 2018, Vanover et al., "ITI-007 (Lumateperone) for The treatment of Agitation in Patients with Dementia, Including Alzheimer's Disease," *Alzheimer's & Dementia* vol. 14, Issue 7S Part 12. (Year: 2018). cited by examiner

Peterson, et al., "Expanding the Scope of Crystal Form Evaluation in Pharmaceutical Science", *J Pharm Pharmaceut Sci.*, 9(3), pp. 317-326, (2006). cited by applicant

"Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar," ClinicalTrials.gov (Identifier: NCT02600494), 5 pages, (2015). cited by applicant

Aiken, C., "An Overview of Atypical Antipsychotics for Bipolar Depression," published on Jan. 3, 2020 at <https://www.psychiatrytimes.com/view/overview-atypical-antipsychotics-bipolar-depression>, 11 pages. cited by applicant

Barman, R. et al., "Newer Antipsychotics: Brexpiprazole, Cariprazine, and Lumateperone: A Pledge or Another Unkept Promise?," *World J. Psychiatr.*, vol. 11, No. 12, pp. 1228-1238, (2021). cited by applicant

Bavin, M., "Polymorphism in Process Development," *Chemistry & Industry*, pp. 527-529, (1989). cited by applicant

Berge, S. et al., "Pharmaceutical Salts," *J. Pharm. Sci.*, vol. 66, No. 1, pp. 1-19, (1977). cited by applicant

Bharate, S., "Recent Developments in Pharmaceutical Salts: FDA Approvals From 2015 to 2019," *Drug Discovery Today*, vol. 26, No. 2, pp. 384-398, (2021). cited by applicant

Brittain, H. et al., "Chapter 5: Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," *Polymorphism in Pharmaceutical Solids*, 25 pages, (1999). cited by applicant

Calabrese, J. et al., "Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial," *American Journal of Psychiatry*, vol. 178, No. 12, pp. 1098-1106, (2021), published online Sep. 23, 2021, DOI: <https://doi.org/10.1176/appi.aip.2021.20091339>. cited by applicant

Correll, C. et al., "Efficacy and Safety of Lumateperone for Treatment of Schizophrenia A Randomized Clinical Trial," *JAMA Psychiatry*, vol. 77, No. 4, pp. 349-358, (2020). cited by applicant

Davis, R. et al., "ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders," *Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014* (2014) (poster presentation). cited by applicant

Davis, R. et al., "Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia," *The Journal of Prevention of Alzheimer's Disease*, 2(4):302 (2015) (*Clinical Trials in Alzheimer's Disease (CTAD) Congress, Symposium Summary OC51*). cited by applicant

Davis, R. et al., "Lumateperone (ITI-007), A Novel Drug in Development for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease: Rationale and Clinical Design," *The Journal of Prevention of Alzheimer's Disease*, 4(4):372 (2017) (*Clinical Trials in Alzheimer's Disease (CTAD) Congress, Symposium Summary P93*). cited by applicant

Edinoff, A. et al., "Lumateperone for the Treatment of Schizophrenia," *Psychopharmacology Bulletin*, vol. 50, No. 4, pp. 32-59, (2020). cited by applicant

Grant, D., "Polymorphism in Pharmaceutical Solids", Chapter 1, pp. 1-10 (1999). cited by applicant

Harvey, P. et al., "Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patient with Schizophrenia," Abstract presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting: May 29-Jun. 1, 2018: Miami, FL. cited by

applicant

Hlavinka, E., "Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo," Medpage Today, 7 pages, (2020); <https://www.medpagetoday.com/meetingcoverage/psychcongress/88584>. cited by applicant

Kendrick, T., "The Newer, 'Atypical' Antipsychotic Drugs—Their Development and Current Therapeutic Use," British J. General Practice, vol. 49, pp. 745-749, (1999). cited by applicant

Khorana, N. et al., "Gamma-Carbolines: Binding at 5-HT_{5A} Serotonin Receptors," Bioorganic & Medicinal Chemistry, vol. 11, D. 717-722, p. 718, Table 1, (2003). cited by applicant

Kumar, B. et al., "Lumateperone: A New Treatment Approach for Neuropsychiatric Disorders," Drugs of Today, vol. 54, No. 12, pp. 713-719, (2018). cited by applicant

Paulekuhn, G. et al., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database," J Med Chem., vol. 50, pp. 6665-6672, (2007). cited by applicant

Press Release, "Intra-Cellular Therapies Announces Additional Results From Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia," Intra-Cellular Therapies, Press Release Date: Nov. 21, 2014. cited by applicant

Press Release, "Intra-Cellular Therapies Announces Top-Line Results from the Second Phase 3 Trial of ITI-007 in Patients with Schizophrenia (Study '302)", Intra-Cellular Therapies, Press Release Date: Sep. 28, 2016, 8 pages, available at: <https://globenewswire.com/news-release/2016/09/28/875435/0/en/Intra-Cellular-Therapies-Announces-Top-Line-Results-from-the-Second-Phase-3-Trial-of-ITI-007-in-Patients-with-Schizophrenia-Study-302.html>. cited by applicant

Press Release, "Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial With ITI-007 in Patients with Sleep Maintenance Insomnia.", Intra-Cellular Therapies, Press Release Date: Mar. 10, 2009, 3 pages, available at: <https://ir.intracellulartherapies.com/static-files/375e1667-6457-4cd9-95dc-616ca3b5d02b>. cited by applicant

Press Release, "Intra-Cellular Therapies Announces Positive Top-Line Results from a Phase 3 Trial of Lumateperone in Patient with Bipolar Depression," Intra-Cellular Therapies, Press Release Date: Jul. 8, 2019. cited by applicant

Press Release, "Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting," Intra-Cellular Therapies, Press Release Date: May 31, 2018, (<https://ir.intracellulartherapies.com/newsreleases/>). cited by applicant

Saal, C. et al., "Pharmaceutical Salts: A Summary on Doses of Salt Formers from the Orange Book," European Journal of Pharmaceutical Sciences, vol. 49, pp. 614-623, (2013). cited by applicant

Satlin, A. et al., "ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease," Alzheimer's & Dementia, vol. 14, No. 7, pp. 678-679, (2018), (Alzheimer's Assoc. International Conference 2018, summary of Poster P2-032). cited by applicant

Satlin, A. et al., "ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease," Poster P2-032, Alzheimer's Assoc. International Conference 2018, (2018). cited by applicant

Serajuddin, A., "Salt formation to improve drug solubility," Advanced Drug Delivery Reviews, vol. 59, pp. 603-616, (2007). cited by applicant

Stahl & Wermouth (Eds.), "Handbook of Pharmaceutical Salts Properties, Selection, and Use," Wiley-VCH, pp. 167-168, 170-173, 216-217 (2002). cited by applicant

Stahl & Wermouth (Eds.), "Handbook of Pharmaceutical Salts Properties, Selection, and Use," Wiley-VCH, pp. 258-261 (2002). cited by applicant

Vanover, K. et al., "Dopamine D₂ receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia," Neuropsychopharmacology, vol. 44,

pp. 598-605, (2019). cited by applicant

Vanover, K. et al., "ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses," *International Clinical Psychopharmacology*, vol. 26, e56, 1 page, (2011). cited by applicant

Vanover, K. et al., "A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate," Abstract presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 29-Jun. 1, 2018; Miami, FL. cited by applicant

Vanover, K. et al., "Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders," *European Neuropsychopharmacology*, vol. 27, pp. S660-S661 (2017) (Summary of ECNP Poster p. 1.g.038). cited by applicant

Vanover, K. et al., Abstracts of the 13th International Congress on Schizophrenia (ICOSR) (Apr. 2-6, 2011), *Schizophrenia Bull.*, vol. 37, Suppl. 1., p. 325, (2011). cited by applicant

Vyas, P. et al., "An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia," *Expert Opinion on Pharmacotherapy*, vol. 21, No. 2, pp. 139-145, (2020); <https://doi.org/10.1080/14656566.2019.1695778>. cited by applicant

Wennogle, L. et al., "Activation of NMDA and AMPA Receptors by Lumateperone (ITI-007): Implications for Antidepressant Activity," Abstract presented at the 2017 Collegium Internationale Neuro-Psychopharmacologicum (CINP) Thematic Meeting: Treatment Resistant Depression; Jul. 20-22, 2017; Prague. cited by applicant

Balbach, et al. "Pharmaceutical evaluation of early development candidates 'the 100 mg-approach'," *International Journal of Pharmaceutics*, vol. 275, pp. 1-12 (2004). cited by applicant

Bastin, "Salt Selection and Optimized Procedures for Pharmaceutical New Chemical Entities", *Organic Process and Research Development*, vol. 4, No. 5, pp. 427-435 (2000). cited by applicant

Byrn, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations," vol. 12, No. 7, pp. 945-954 (1995). cited by applicant

Caira M.R., "Crystalline Polymorphism of Organic Compounds," *Design of Organic Solids, Topics in Current Chemistry*, 198:163-208 (1998). cited by applicant

Davis, et al. "ITI-007 demonstrates brain occupancy at serotonin 5-HT_{2A} and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers," *Psychopharmacology*, Published Online Apr. 7, 2015, 10 pages. cited by applicant

Davis, et al., "ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes," *Expert Review of Neurotherapeutics*, vol. 16, No. 6, pp. 601-614 (2016). cited by applicant

Gadade, et al., "Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development," *Adv Pharm Bull*, vol. 6, No. 4, pp. 479-494, (2016). cited by applicant

Grant, "Polymorphism in Pharmaceutical Solids", Chapter 1, pp. 1-10 (1999). cited by applicant

Guillory, "Polymorphism in Pharmaceutical Solids", Chapter 5, pp. 183-226 (1999). cited by applicant

Haynes, "Occurrence of Pharmaceutically Acceptable Anions and Cations in the Cambridge Database," *Journal of Pharmaceutical Sciences*, vol. 94, No. 10, pp. 2111-2120 (2005). cited by applicant

International Search Report for International Application No. PCT/US2018/052922, mailed Nov. 26, 2018, 3 pages. cited by applicant

Jain, et al., "Polymorphism in Pharmacy", *Indian Drugs*, vol. 23, No. 6, pp. 315-316 (1986). cited by applicant

Lee, et al., "Novel, Highly Potent, Selective 5-HT_{2A}/D₂ Receptor Antagonists as Potential Atypical Antipsychotics," *Bioorg. Med. Chem. Lett.*, vol. 13, pp. 767-770, (2003). cited by applicant

Li, et al., "Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders," vol. 57, pp. 2670-2682 (2014). cited by applicant

Li, et al., "Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future," Current Topics in Medicinal Chemistry, vol. 16, pp. 3385-3403 (2016). cited by applicant

Marek, et al., "Synergistic Action of 5-HT_{2A} Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders," Neuropsychopharmacology, vol. 28, pp. 402-412 (2003). cited by applicant

Nagai, et al., "Synthesis of 2, 3, 4, 4a, 5, 9b-hexahydro-1H-pyrido [4,3-b] indole derivatives and their central nervous system activities." Journal of Medicinal Chemistry, vol. 22, No. 6, pp. 677-683, (1979). cited by applicant

Newman, et al., "Solid-State Analysis of the Active Pharmaceutical Ingredient in Drug Products," Drug Discovery Today, vol. 8, No. 9, pp. 898-903 (2003). cited by applicant

Savjani et al., "Drug Solubility: Importance and Enhancement Techniques," International Scholarly Research Network Pharmaceutics (2012), vol. 2012, pp. 1-10. cited by applicant

Singhal, et al., "Drug polymorphism and dosage form design: a practical perspective", Advanced Drug Delivery Reviews, vol. 56, pp. 335-347 (2004). cited by applicant

Snyder, et al., "Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission," Psychopharmacology, vol. 232, pp. 605-621 (2015). cited by applicant

Vippagunta, et al., "Crystalline Solids," Advanced Drug Delivery Reviews, vol. 48, 24 pages, (2001). cited by applicant

Bastin, R. et al., "Salt Selection and Optimized Procedures for Pharmaceutical New Chemical Entities," Organic Process and Research Development, vol. 4, No. 5, pp. 427-435, (2000). cited by applicant

Dutheil, S., et al. "Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation," The Journal of Neuroscience, vol. 43, No. 5, pp. 863-877, (2023). cited by applicant

Gramigna, J, "Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders," American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages. cited by applicant

Lee, T. et al., "Novel, Highly Potent, Selective 5-HT_{2A}/D₂ Receptor Antagonists as Potential Atypical Antipsychotics," Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 767-770, (2003). cited by applicant

Liebermann, J. et al., "ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial," Biological Psychiatry, vol. 79, pp. 952-961, (2016). cited by applicant

Snyder, G. et al., "Chapter 11: A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia," Advances in Pharmacology, vol. 90, pp. 253-276, 31 pages, (2021). cited by applicant

Suppes, T. et al., "Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial," Bipolar Disorders, vol. 25, pp. 478-488, 11 pages, (2023). cited by applicant

Primary Examiner: Barsky; Jared

Attorney, Agent or Firm: Hoxie & Associates LLC

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a divisional application of U.S. nonprovisional application Ser. No. 16/649,515, filed on Mar. 20, 2020, which is a national stage application under 35 U.S.C. § 371 of International Application No. PCT/US2018/052922, filed on Sep. 26, 2018, which claims priority to and the benefit of U.S. Provisional Application No. 62/563,341, filed on Sep. 26, 2017, the contents of which are hereby incorporated by reference in its entirety.

FIELD

(1) This disclosure relates to certain novel salts and crystal forms of a substituted heterocycle fused gamma-carboline, the manufacture thereof, pharmaceutical compositions thereof, and use thereof, e.g., in the treatment of diseases or abnormal conditions involving or mediated by the 5-HT_{2A} receptor, serotonin transporter (SERT), and/or dopamine D₁/D₂ receptor signaling pathways.

BACKGROUND

(2) 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H -pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (sometimes referred to as 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone, and also known as Lumateperone or as ITI-007), has the following structure:

(3) ##STR00001##

(4) ITI-007 is a potent 5-HT_{2A} receptor ligand (K_i=0.5 nM) with strong affinity for dopamine (DA) D₂ receptors (K_i=32 nM) and the serotonin transporter (SERT) (K_i=62 nM) but negligible binding to receptors (e.g., H₁ histaminergic, 5-HT_{2C}, and muscarinic) associated with cognitive and metabolic side effects of antipsychotic drugs. ITI-007 is currently in clinical trials, i.e., for treatment of schizophrenia. While ITI-007 is a promising drug, its production and formulation present challenges. In free base form, ITI-007 is an oily, sticky solid, with poor aqueous solubility. Making salts of the compound has proven to be unusually difficult. A hydrochloride salt form of ITI-007 was disclosed in U.S. Pat. No. 7,183,282, but this particular salt form was hygroscopic and showed poor stability. It was obtained by precipitation from diethyl ether. A toluenesulfonic acid addition salt (tosylate) of ITI-007 was finally identified and described in WO 2009/114181, and its equivalent US 2011/112105, the contents of each of which are hereby incorporated by reference in their entireties.

(5) There is a need for alternative stable and pharmaceutically acceptable salts and polymorphs of ITI-007.

SUMMARY

(6) In an effort to find new salts and polymorphs of ITI-007, an extensive salt screen was undertaken. ITI-007 does not readily form salts with other common, pharmaceutically acceptable acids, despite the good solubility of the free base in a variety of organic solvents. Eventually, a toluenesulfonic acid addition salt (tosylate) was prepared, as described in WO 2009/114181 and US 2011/112105, but no other stable salts were found. Finally, a major salt screen was carried out, wherein the free base compound was studied in different solvent systems and under different conditions, and then systematically screened using a selection of over 100 acids under different conditions and with different solvent, co-solvent and anti-solvent systems, to identify possible salt forms. Following extensive screening and experimentation, three new hydrochloride polymorphs were discovered. These hydrochloride salt forms are crystalline and stable.

(7) The disclosure thus provides new hydrochloride salt forms of ITI-007, which are especially advantageous for use in the preparation of galenic formulations, together with methods of making and using the same.

(8) Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific

examples, while indicating preferred embodiments of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

- (1) The present invention will become more fully understood from the detailed description and the accompanying drawings, wherein:
- (2) FIG. 1 depicts an X-ray powder diffraction pattern for an ITI-007 hydrochloride salt crystal (Polymorph 1).
- (3) FIG. 2 depicts an X-ray powder diffraction pattern for an ITI-007 hydrochloride salt crystal (Polymorph 2).
- (4) FIG. 3 depicts an X-ray powder diffraction pattern for an ITI-007 hydrochloride salt crystal (Polymorph 3).
- (5) FIG. 4 depicts an X-ray powder diffraction patterns obtained from ITI-007 hydrochloride salt competitive slurry experiments in 1-butanol (top: 50° C.; bottom: RT).

DETAILED DESCRIPTION

- (6) The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.
- (7) As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
- (8) Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.
- (9) In a first embodiment, the invention provides 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl) -butan-1-one (ITI-007) in stable hydrochloride salt form (Salt 1). The invention therefore provides the following:
- 1.1. Salt 1 in solid form. 1.2. Salt 1 or 1.1 in crystalline form, e.g., dry crystalline form. 1.3. Salt 1.2 in a homogeneous crystal form, free or substantially free of other forms, e.g., free or substantially free, e.g., less than 10 wt. %, preferably less than about 5 wt. %, more preferably less than about 2 wt. %, still preferably less than about 1 wt. %, still preferably less than about 0.1%, most preferably less than about 0.01 wt. %, of amorphous forms. 1.4. Any foregoing form of Salt 1 in crystalline form, when crystallized from a mixture of hydrochloric acid and ITI-007, e.g. in an organic solvent, e.g., comprising toluene, ethyl acetate, cyclopropylmethyl ether (CPME), acetonitrile, 1-butanol, or mixtures thereof; e.g., wherein the hydrochloric acid and ITI-007 are in a molar ratio of about 1:1 or about 1:2. 1.5. Any foregoing form of Salt 1 which is a solvate, e.g., an ethyl acetate solvate, or a toluene solvate, or a CPME solvate, or a 1-butanol solvate. 1.6. Any foregoing form of Salt 1 which is not a solvate. 1.7. Any foregoing form of Salt 1 which is a hydrate. 1.8. Any foregoing form of Salt 1 which is not a hydrate. 1.9. Any foregoing form of Salt 1 formed by combining free ITI-007 free base and hydrochloric acid in a molar ratio from 1:1 to 1:2, e.g., a 1:1 molar ratio or a 1:2 molar ratio. 1.10. Any foregoing form of Salt 1, wherein the salt is formed from a slurry experiment in ethyl acetate to yield Polymorph 1, e.g., using a 1:1 molar ratio of ITI-007 free base to hydrochloride acid in CPME 1.11. Salt 1.10, wherein a DSC analysis shows two endothermic events, at 117° C. and 228° C., e.g. wherein a DSC/TGA analysis shows the first endothermic event at T.sub.onset=110° C., T.sub.peak=117° C. and $\Delta E=-15$ J/g, and the second event at T.sub.onset=218° C., T.sub.peak=228° C. and $\Delta E=-39$ J/g. 1.12. Salt 1.10 or 1.11, in the

form of a crystal having an X-ray powder diffraction pattern corresponding to the d-spacing and/or angle (2-theta) values of the following table, for example at least five, or at least six, or at least seven, or at least eight of said values, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter, e.g., comprising at least those peaks having a relative intensity of at least 0.4, e.g., at least 0.5, e.g., at least 0.6, e.g., comprising peaks 1, 2, 6, 7, 8, and 9:

(10) TABLE-US-00001 XRPD (Cu anode, Ni filter) for Hydrochloride Salt Crystal Polymorph 1 #

| Angle d Value Rel. Intensity | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|----------|----------|---------|---------|----------|---|--------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|---|---|----------|---------|----------|---|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|---------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|---------|----------|---------|----|----------|----------|----------|----|---------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|----|----------|----------|----------|-------|
| 7.28967 | 12.11707 | 0.086731 | 10.2809 | 8.59734 | 0.200258 | 3 | 10.442 | 8.465061 | 0.200747 | 4 | 12.21318 | 7.241127 | 0.433615 | 5 | 13.42102 | 6.592047 | 0.224916 | 6 | 15.23882 | 5.809543 | 0.438444 | 7 | 16.28812 | 5.437572 | 1 | 8 | 16.80838 | 5.27042 | 0.215476 | 9 | 18.82491 | 4.710149 | 0.181319 | 10 | 19.56592 | 4.533406 | 0.249163 | 11 | 21.14059 | 4.199153 | 0.652782 | 12 | 22.06027 | 4.026127 | 0.400921 | 13 | 22.07126 | 4.024148 | 0.42148 | 14 | 22.62619 | 3.926692 | 0.559073 | 15 | 23.78436 | 3.738039 | 0.298317 | 16 | 24.30932 | 3.658491 | 0.445871 | 17 | 25.02641 | 3.555265 | 0.440086 | 18 | 26.3953 | 3.373907 | 0.26406 | 19 | 26.44407 | 3.367795 | 0.277233 | 20 | 26.5014 | 3.360641 | 0.252958 | 21 | 27.23728 | 3.271492 | 0.230046 | 22 | 29.35735 | 3.039883 | 0.073715 | 23 | 33.52987 | 2.670518 | 0.091379 | 1.13. |

Any form of Salt 1.10-1.12, in the form of a crystal having an X-ray powder diffraction pattern corresponding to FIG. 1, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., an X-ray powder diffraction pattern corresponding to FIG. 1 generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.14. Any form of Salt 1.10-1.13, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values selected from the group consisting of about 7.29, 10.28, 10.44, 12.21, 13.42, 15.24, 16.29, 16.81, 18.82, 19.57, 21.14, 22.06, 22.07, 22.63, 23.78, 24.31, 25.03, 26.40, 26.44, 26.50, 27.24, 29.36, and 33.53, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.15. Any form of Salt 1.10-1.14, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having d-spacing values selected from the group consisting of about 12.12, 8.60, 8.47, 7.24, 6.59, 5.81, 5.44, 5.27, 4.71, 4.53, 4.20, 4.03, 4.02, 3.93, 3.74, 3.66, 3.56, 3.37, 3.37, 3.36, 3.27, 3.04, and 2.67, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.16. Any form of Salt 1.10-1.15, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values and/or d-spacing values as provided in 1.14 and 1.15. 1.17. Any form of Salt 1.10-1.16, in the form of a crystal having an X-ray powder diffraction powder having relative angle (2-theta) values as provided in the table of embodiment 1.12, wherein the values are shifted by up to ± 0.2 degrees, e.g., wherein the values are substantially uniformly shifted by up to ± 0.2 degrees. 1.18. Any form of Salt 1 or 1.1-1.9, wherein the salt is formed from a slurry experiment in toluene to yield Polymorph 2, e.g., using a 1:1 molar ratio of ITI-007 free base to hydrochloride acid in CPME. 1.19. Salt 1.18, wherein a DSC analysis shows two endothermic events, at 121° C. and 228° C., e.g. wherein a DSC/TGA analysis shows a first endothermic event at T.sub.onset=108° C., T.sub.peak=121° C. and $\Delta E = -23$ J/g, and the second event at T.sub.onset=215° C., T.sub.peak=228° C. and $\Delta E = -57$ J/g. 1.20. Salt 1.18 or 1.19, in the form of a crystal having an X-ray powder diffraction pattern corresponding to the d-spacing and/or angle (2-theta) values of the following table, for example at least five, or at least six, or at least seven, or at least eight of said values, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter, e.g., comprising at least those peaks having a relative intensity of

at least 0.4, e.g., at least 0.5, e.g., at least 0.6, e.g., comprising peaks 1, 2, 6, 7, 8, and 9:

(11) TABLE-US-00002 XRPD (Cu anode, Ni filter) for Hydrochloride Salt Crystal Polymorph 2 #
Angle d Value Rel. Intensity 1 10.51587 8.405758 0.510923 2 11.72088 7.54414 0.189459 3
12.09875 7.309357 0.796857 4 13.11974 6.74274 0.311634 5 14.24802 6.21123 0.24302 6
16.03021 5.524469 0.999989 7 16.56551 5.347139 0.83136 8 16.6931 5.306556 0.7834 9
18.93689 4.682549 0.251913 10 19.84092 4.471187 0.162883 11 21.09046 4.209022 0.703611 12
20.84009 4.25902 0.269821 13 21.77743 4.077775 0.750891 14 22.29105 3.984963 1 15 22.46965
3.953692 0.838087 16 24.20198 3.674474 0.667304 17 24.61919 3.61314 0.846243 18 26.8244
3.320902 0.36495 19 28.28183 3.152993 0.182531 1.21. Any form of Salt 1.18-1.20, in the form of

a crystal having an X-ray powder diffraction pattern corresponding to FIG. 2, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., an X-ray powder diffraction pattern corresponding to FIG. 2 generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.22. Any form of Salt 1.18-1.21, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values selected from the group consisting of about 10.52, 11.72, 12.10, 13.12, 14.25, 16.03, 16.57, 16.69, 18.94, 19.84, 21.09, 20.84, 21.78, 22.29, 22.47, 23.20, 24.62, 26.82, and 28.28, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.23. Any form of Salt 1.18-1.22, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having d-spacing values selected from the group consisting of about 8.41, 7.54, 7.31, 6.74, 6.21, 5.52, 5.35, 5.31, 4.68, 4.47, 4.21, 4.26, 4.08, 3.98, 3.95, 3.67, 3.61, 3.32, and 3.15, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.24. Any form of Salt 1.18-1.23, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values and/or d-spacing values as provided in 1.22 and 1.23. 1.25. Any form of Salt 1.18-1.24, in the form of a crystal having an X-ray powder diffraction powder having relative angle (2-theta) values as provided in the table of embodiment 1.20, wherein the values are shifted by up to ± 0.2 degrees, e.g., wherein the values are substantially uniformly shifted by up to ± 0.2 degrees. 1.26. Any form of Salt 1 or 1.1-1.9, wherein the salt is formed from a slurry experiment in CPME to yield Polymorph 3, e.g., using a 1:1 molar ratio of ITI-007 free base to hydrochloride acid in CPME. 1.27. Salt 1.26, wherein a DSC analysis shows two endothermic events, at 122° C. and 209° C., e.g. wherein a DSC/TGA analysis shows a first endothermic event at T.sub.onset=97° C., T.sub.peak=122° C. and $\Delta E=-38$ J/g, and the second event at T.sub.onset=192° C., T.sub.peak=209° C. and $\Delta E=-13$ J/g. 1.28. Salt 1.26 or 1.27, in the form of a crystal having an X-ray powder diffraction pattern corresponding to the d-spacing and/or angle (2-theta) values of the following table, for example at least five, or at least six, or at least seven, or at least eight of said values, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter, e.g., comprising at least those peaks having a relative intensity of at least 0.4, e.g., at least 0.5, e.g., at least 0.6, e.g., comprising peaks 1, 2, 6, 7, 8, and 9:

(12) TABLE-US-00003 XRPD (Cu anode, Ni filter) for Hydrochloride Salt Crystal Polymorph 3 #
Angle d Value Rel. Intensity 1 6.113585 14.44517 0.204101 2 10.09204 8.757802 0.489434 3
10.35476 8.536179 0.605859 4 11.54239 7.660397 0.585963 5 12.08467 7.317844 1 6
12.93047 6.841012 0.161332 7 13.23207 6.685754 0.254659 8 15.77195 5.614344 0.712069 9
18.19631 4.871422 0.250223 10 19.51964 4.544048 0.326853 11 20.92257 4.242415 0.744994 12
23.86984 3.724845 0.732022 13 24.96878 3.563339 0.326213 14 26.39552 3.373879 0.575626

1.29. Any form of Salt 1.26-1.28, in the form of a crystal having an X-ray powder diffraction pattern corresponding to FIG. 3, e.g., taking into account potential variations due to sample purity and instrument variation, for example 2 θ shifts due to variation in X-ray wavelength, e.g., an X-ray powder diffraction pattern corresponding to FIG. 3 generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.30. Any form of Salt 1.26-1.29, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values selected from the group consisting of about 6.11, 10.09, 10.35, 11.54, 12.08, 12.93, 13.23, 15.77, 18.20, 19.52, 20.92, 23.87, 24.97, and 26.40, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.31. Any form of Salt 1.26-1.30, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having d-spacing values selected from the group consisting of about 14.45, 8.76, 8.54, 7.66, 7.32, 6.84, 6.69, 5.61, 4.87, 4.54, 4.24, 3.73, 3.56, and 3.37, taking into account potential variations due to sample purity and instrument variation, wherein the X-ray powder diffraction pattern is generated using an X-ray diffractometer with a copper anode and a nickel filter. 1.32. Any form of Salt 1.26-1.31, in the form of a crystal having an X-ray powder diffraction pattern having at least 5, or at least 6, or at least 7, or at least 8, peaks having angle (2-theta) values and/or d-spacing values as provided in 1.30 and 1.31. 1.33. Any form of Salt 1.26-1.32, in the form of a crystal having an X-ray powder diffraction powder having relative angle (2-theta) values as provided in the table of embodiment 1.28, wherein the values are shifted by up to ± 0.2 degrees, e.g., wherein the values are substantially uniformly shifted by up to ± 0.2 degrees. 1.34. Any foregoing form of Salt 1 wherein the ITI-007 is deuterated, e.g., wherein the deuterium:protium ratio at one or more specified positions in the molecule is significantly higher, e.g., at least $2\times$, for example at least $10\times$ higher, than the natural isotope ratios or the isotope ratios at other positions in the molecule; for example, any foregoing form of Salt 1 wherein the —CH.sub.2— adjacent to the methylated nitrogen moiety and/or adjacent to the carbonyl moiety of ITI-007 is deuterated, e.g., is in the form of —CHD— or —CD.sub.2— at levels which are significantly higher than the natural deuterium:protium isotope ratio or the deuterium:protium isotope ratio at other positions in the molecule, and/or wherein the methyl group is deuterated, e.g., is CD.sub.3—, e.g., at levels which are significantly higher than the natural deuterium:protium isotope ratio or the deuterium:protium isotope ratio at other positions in the molecule, e.g., as described in WO 2015/154025, the contents of which are incorporated herein by reference. 1.35. Any foregoing form of Salt 1 exhibiting any combination of characteristics as described in 1.1-1.34.

(13) In another embodiment, the invention provides a process (Process 1) for the production of Salt 1, comprising

(14) (a) reacting 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro -1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) free base with hydrochloric acid, e.g., together with an organic solvent (e.g., comprising toluene, ethyl acetate, CPME, acetonitrile, 1-butanol, or mixtures thereof), for example, wherein the hydrochloric acid and ITI-007 are in a molar ratio of from 1:1 to 1:2, or about 1:1, or about 1:2; and

(15) (b) recovering the hydrochloride salt thus formed, e.g., recovering a salt according to any of Salt 1, et seq. above.

(16) In an embodiment of Process 1, the hydrochloric acid is provided as a gas (hydrogen chloride), or as an aqueous solution, or as a solution in an organic solvent, e.g., selected from methanol, ethanol, isopropanol, cyclopropylmethyl ether (CPME), diethyl ether, 1,4-dioxane, or any mixture thereof.

(17) In another embodiment of Process 1, the reaction step (a) comprises dissolving or suspending the ITI-007 free base in an organic solvent, e.g., selected from toluene, ethyl acetate, CPME, acetonitrile, 1-butanol, or mixtures thereof, and adding thereto the hydrochloric acid. In another

embodiment of Process 1, the reaction step (a) comprises combining the ITI-007 free base with the hydrochloric acid and adding thereto an organic solvent, e.g., selected from toluene, ethyl acetate, CPME, acetonitrile, 1-butanol, or mixtures thereof.

(18) In some embodiments of Process 1, the process step (a) is carried out as a batch process, and in other embodiments the process step (a) is carried out as a continuous (flow) process.

(19) In another embodiment, the invention provides a method of purifying 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) in free or salt form, comprising reacting a crude solution of ITI-007 with hydrochloric acid, and recovering the hydrochloride salt thus formed, e.g., in accordance with Process 1, and optionally converting the hydrochloride salt back to ITI-007 free base or to another salt form.

(20) In another embodiment, the invention provides the use of hydrochloric acid in a method of isolating and/or purifying ITI-007.

(21) As used herein, "hydrochloric acid" refers pure (gaseous) hydrogen chloride, hydrochloric acid in water (aqueous hydrochloric acid), or hydrochloric acid in an organic solvent (i.e., hydrogen chloride in an organic solvent), wherein the organic solvent may be selected from any suitable organic solvent capable of dissolving hydrogen chloride, such as, methanol, ethanol, isopropanol, cyclopropylmethyl ether (CPME), diethyl ether, 1,4-dioxane, or any mixture thereof.

(22) In another embodiment, the invention provides a pharmaceutical composition comprising Salt 1, e.g., any of Salt 1.1-1.35, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier.

(23) In another embodiment, the invention provides pharmaceutical composition comprising Salt 1, e.g., any of Salt 1.1-1.35, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier, wherein the Salt 1 is predominantly, or is entirely or substantially entirely, in dry crystalline form.

(24) In a particular embodiment, the invention provides a pharmaceutical composition comprising Salt 1, e.g., any of Salt 1.1-1.35, as active ingredient, in combination or association with a pharmaceutically acceptable diluent or carrier, in the form of an injectable depot form, to provide extended release of ITI-007.

(25) In another embodiment, the invention provides Salt 1, e.g., any of Salt 1.1-1.35, or a pharmaceutical composition comprising Salt 1, e.g., any of Salt 1.1-1.35, for use in treating a disease or abnormal condition involving or mediated by the 5-HT_{2A} receptor, serotonin transporter (SERT), and/or dopamine D₁/D₂ receptor signaling pathways, e.g., a disorder selected from obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive-compulsive disorder, sexual disorders, depression, schizophrenia, migraine, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, sleep disorders, conditions associated with cephalic pain, social phobias, or dementia.

(26) In another embodiment, the invention provides a method for the prophylaxis or treatment of a human suffering from a disease or abnormal condition involving or mediated by the 5-HT_{2A} receptor, serotonin transporter (SERT), and/or dopamine D₁/D₂ receptor signaling pathways, e.g., a disorder selected from obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive-compulsive disorder, sexual disorders, depression, schizophrenia, migraine, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, sleep disorders, conditions associated with cephalic pain, social phobias, or dementia, comprising administering to a patient in need thereof a therapeutically effective amount of any of Salt 1, et seq.

EXAMPLES

(27) The following equipment and methods are used to isolate and characterize the exemplified salt forms:

(28) X-ray powder diffraction (XRPD): The X-ray powder diffraction studies are performed using a

Bruker AXS D2 PHASER in Bragg-Brentano configuration, equipment #1549/#2353. The equipment uses a Cu anode at 30 kV, 10 mA; sample stage standard rotating; monochromatization by a β -filter (0.5% Ni). Slits: fixed divergence slits 1.0 mm($=0.61^\circ$), primary axial Soller slit 2.5° , secondary axial Soller slit 2.5° . Detector: Linear detector LYNXEYE with receiving slit 5° detector opening. The standard sample holder (0.1 mm cavity in (510) silicon wafer) has a minimal contribution to the background signal. Measurement conditions: scan range $5\text{--}45^\circ 2\theta$, sample rotation 5 rpm, 0.5 s/step, $0.010^\circ/\text{step}$, 3.0 mm detector slit; and all measuring conditions are logged in the instrument control file. As system suitability, corundum sample A26-B26-S (NIST standard) is measured daily. The software used for data collection is Diffrac.Commander v2.0.26. Data analysis is done using Diffrac.Eva v1.4. No background correction or smoothing is applied to the patterns.

(29) Simultaneous thermogravimetry (TGA) and differential scanning calorimetry (DSC) or TGA/DSC analysis: The TGA/DSC studies are performed using a Mettler Toledo TGA/DSC1 Stare System, equipment #1547, auto-sampler equipped, using pin-holed A1-crucibles of 40 μl . Measurement conditions: 5 min 30.0°C ., $30.0\text{--}350.0^\circ\text{C}$. with $10^\circ\text{C}/\text{min}$., N_2 flow of 40 ml/min. The software used for instrument control and data analysis is STARe v12.10.

(30) Differential scanning calorimetry (DSC): The DSC studies are performed using a Mettler Toledo DSC1 STARe System, equipment #1564. The samples are made using A1 crucibles (40 μl ; pierced). Typically 1-8 mg of sample is loaded onto a pre-weighed A1 crucible and is kept at 30°C . for 5 minutes, after which it is heated at $10^\circ\text{C}/\text{min}$ from 30°C . to 350°C . and kept at 350°C . for 1 minute. A nitrogen purge of 40 ml/min is maintained over the sample. As system suitability check Indium and Zinc are used as references. The software used for data collection and evaluation is STARe Software v12.10 build 5937. No corrections are applied to the thermogram.

(31) Polarized light microscopy (PLM): The microscopy studies are performed using an AxioVert 35M, equipped with an AxioCamERc 5s, equipment #1612. The microscope is equipped with four lenses: Zeiss A-Plan $5\times/0.12$, Zeiss A-Plan $10\times/0.25$, LD A-Plan $20\times/0.30$ and Achros TIGMAT $32\times/0.40$. Data collection and evaluation is performed using Carl Zeiss Zen AxioVision Blue Edition Lite 2011 v1.0.0.0 software. A small amount of sample is loaded on an object glass and carefully spread until a thin layer is obtained.

(32) Dynamic Vapour Sorption (DVS): The Dynamic Vapour Sorption studies are performed using a Surface Measurement Systems Ltd. DVS-1 No Video, equipment #2126. The sample is loaded into a balance pan, typically 20-30 mg, and equilibrated at 0% RH. After the material was dried, the RH is increased with 10% per step for 1 hour per increment, ending at 95% RH. After completion of the sorption cycle, the sample was dried using the same method. The software used for data collection is DVSW in v3.01 No Video. Data analysis is performed using DVS Standard Analysis Suite v6.3.0 (Standard).

(33) Particle size distribution (PSD): The particle size distribution studies are performed using a Malvern Instruments Mastersizer, equipment #1712. The Mastersizer uses a 300 RF lens range of $0.05\text{ }\mu\text{m}\text{--}900\text{ }\mu\text{m}$. Polydisperse is used as analysis model. Measurement conditions: before each sample measurement a background measurement is performed, the background scan time is 12 seconds (12000 snaps). Each sample is dispersed in Multipar G, refractive index of 1.42. The obscuration range on sample dispersion is between 10%-30%. Each sample is measured 6 times at $t=0$ and $t=30$ minutes and the measurement scan time is 10 seconds (10000 snaps). The targeted stirring speed of the sample dispersion unit is 2000 ± 10 rpm. Data collection and evaluation is performed using Mastersizer S Version 2.19 software.

(34) Capillary Melting Point: The capillary melting point is determined on a Büchi Melting Point B-545, equipment #000011, conform USP guidelines.

(35) X-ray fluorescence (XRF): The X-ray fluorescence studies are performed using a Bruker AXS S2 RANGER, equipment #2006. Using an end-window X-ray tube with Palladium anode and an ultra-thin Beryllium window ($75\text{ }\mu\text{m}$) for superior light element analysis. As detector the Xflash V5

detector with Cr, Ti, Al, Ta collimator (energy resolution <129 eV FWHM at 100 000 cps Mn α) is used. The S2 Ranger is equipped with an autosampler with integrated 28 position X-Y automatic sample changer with exchangeable tray, which allows maximum sample diameter of 40 mm. Samples are mounted in steel rings of 51.5 mm diameter for automatic operation. Measurement conditions: disposable liquid cups (35 mm inner diameter, 40 mm outer diameter) with polypropylene foil 5 μ m. As system suitability check a copper disk is measured daily and a glass disk, containing several elements, is measured weekly. The software used for data collection is S2 Ranger Control Software V4.1.0. Data analysis is performed using SPECTRA EDX V2.4.3 evaluation software. No background correction or smoothing is applied to the patterns.

(36) Fourier transform infrared spectroscopy (FT-IR): The FT-IR studies are performed using a Thermo Scientific Nicolet iS50, equipment #2357. An attenuated total reflectance (ATR) technique was used with a beam splitter of KBr. Experiment setup of the collected sample is used number of scans 16 with a resolution of 4 from 400 cm^{sup.}-1 to 4000 cm^{sup.}-1. The software OMNIC version 9.2 is used for data collection and evaluation.

(37) Thermogravimetric analysis (TGA) with infrared spectroscopy (TGA-IR): In TGA-IR, the off-gassing materials are directed through a transfer line to a gas cell, where the infrared light interacts with the gases. The temperature ramp and first derivative weight loss information from the TGA is shown as a Gram-Schmidt (GS) profile; the GS profile essentially shows the total change in the IR signal relative to the initial state. In most cases, the GS and the derivative weight loss will be similar in shape, although the intensity of the two can differ. For this experiment are two devices coupled to each other. The TGA studies are performed using a Mettler Toledo TGA/DSC1 STARe System with a 34-position auto sampler, equipment #1547. The samples are made using A1 crucibles (100 μ l; pierced). Typically 20-50 mg of sample is loaded into a pre-weighed A1 crucible and is kept at 30° C. for 5 minutes after which it is heated at 10° C./min from 30° C. to 350° C. A nitrogen purge of 40 ml/min is maintained over the sample. The TGA-IR module of the Nicolet iS50 is coupled to the TGA/DSC1. The IR studies were performed using a Thermo Scientific Nicolet iS50, equipment #2357. Experiment setup of the collected series, the profile Gram-Schmidt is used number of scans 10 with a resolution of 4. The software OMNIC version 9.2 is used for data collection and evaluation.

(38) High performance liquid chromatography (HPLC): The high performance liquid chromatography analyses are performed on LC-31, equipped with an Agilent 1100 series G1322A degasser equipment #1894, an Agilent 1100 series G1311A quaternary pump equipment #1895, an Agilent 1100 series G1313A ALS equipment #1896, an Agilent 1100 series G1318A column equipment #1897 and an Agilent 1100 series G1314A VWD equipment #1898/LC-34, equipped with an Agilent 1200 series G1379B degasser equipment #2254, an Agilent 1100 series G1311A quaternary pump equipment #2255, Agilent 1100 series G1367A WPALS equipment #1656, an Agilent 1100 series G1316A column equipment #2257 and an Agilent 1100 series G1315B DAD equipment #2258. Data is collected and evaluated using Agilent ChemStation for LC systems Rev. B.04.02[96]. Solutions are prepared as follows: Mobile phase A: Add 800 ml of MilliQ water to a 1 L volumetric flask. Add 1 ml of TFA and homogenize. Fill up to the mark with MilliQ; Mobile phase B: Add 800 ml of Acetonitrile to a 1 L volumetric flask. Add 1 ml of TFA and homogenize. Fill up to the mark with Acetonitrile; Diluent: 50/50 MeOH/ACN.

Example 1: Salt Crystal Screen

(39) Solubility of ITI-007 free base in various solvents is evaluated, and based on the results of the solubility range, suitable solvents are selected for the salt screen. The salt screen is divided into seven separate screens, using 90 different counterions, six different solvents, and including four different crystallization methods (slurry crystallization, cooling crystallization, evaporation and precipitation). The counterions are selected based upon availability and potential suitability to form pharmaceutically acceptable acid addition salts. They include the class I, II and III acids identified in Stahl P. H., Wermuch C. G. (editors), Handbook of Pharmaceutical Salts, IUPAC (2008). A total

of 624 counterion/solvent/ratio variations are tested, and each of these is studied using each of the four crystallization methods. Of the 624 combinations tested, only nine combinations produce candidate crystalline salts: six hydrochloric acid conditions, and one condition each for oxalic acid, cyclamic acid and 4-aminosalicylic acid.

(40) For the hydrochloric acid screens, both hydrochloric acid in CPME and hydrochloric acid in isopropanol are used. The molar ratio of free base to acid is 1:1 or 1:2. The reaction solvents screened include acetonitrile, methanol, isopropanol, ethyl acetate, toluene and CPME.

(41) Candidate crystalline salts are observed for the following HCl conditions: (1) HCl/CPME in CPME solvent at a 1:1 molar ratio (slurry crystallization); (2) HCl/CPME in CPME solvent at a 1:2 molar ratio (slurry crystallization); (3) HCl/CPME in toluene solvent at a 1:2 molar ratio (slurry crystallization); (4) HCl/CPME in ethyl acetate solvent at a 1:2 molar ratio (slurry crystallization); (5) HCl/CPME in toluene solvent at a 1:1 molar ratio (cooling crystallization); and (6)

HCl/isopropanol in ethyl acetate solvent at a 1:2 molar ratio (precipitation crystallization). The candidate crystalline salts are each obtained as powders, varying in color from yellow to grey. FT-IR analysis confirms these candidates to be salts, each showing approximately 70% similarity with the free base and showing HCl present. XRPD analysis confirms that each of these candidates are crystalline. LC-MS analysis confirms that there is no decomposition of the free base structure.

(42) To confirm the formation of new hydrochloride salt crystals, scale-up experiments are conducted as follows.

Example 2: Hydrochloride Crystal Salt Polymorph 1

(43) Approximately one gram of ITI-007 free base is added to ethyl acetate solvent at a concentration of 100 mg/mL. Hydrochloric acid in CPME solution is added to provide a 1:1 molar ratio of ITI-007 free base to HCl. The mixture is slurried at 50° C. overnight. The mixture is allowed to cool down to room temperature and is filtered and dried to give a yellow/brown solid. XRPD analysis shows the hydrochloride to be a crystalline solid. The XRPD pattern is shown in FIG. 1; the peaks are identified in tabular form in table 1:

(44) TABLE-US-00004 TABLE 1 XRPD peak list hydrochloride salt polymorph 1 # Angle d Value Rel. Intensity 1 7.28967 12.11707 0.086731 2 10.2809 8.59734 0.200258 3 10.442 8.465061 0.200747 4 12.21318 7.241127 0.433615 5 13.42102 6.592047 0.224916 6 15.23882 5.809543 0.438444 7 16.28812 5.437572 1 8 16.80838 5.27042 0.215476 9 18.82491 4.710149 0.181319 10 19.56592 4.533406 0.249163 11 21.14059 4.199153 0.652782 12 22.06027 4.026127 0.400921 13 22.07126 4.024148 0.42148 14 22.62619 3.926692 0.559073 15 23.78436 3.738039 0.298317 16 24.30932 3.658491 0.445871 17 25.02641 3.555265 0.440086 18 26.3953 3.373907 0.26406 19 26.44407 3.367795 0.277233 20 26.5014 3.360641 0.252958 21 27.23728 3.271492 0.230046 22 29.35735 3.039883 0.073715 23 33.52987 2.670518 0.091379

(45) The hydrochloride salt is also analyzed by DSC/TGA, DVS, HPLC, .sup.1H-NMR and FT-IR. DSC/TGA analysis shows two endothermic events, the first endothermic event at T.sub.onset=110° C., T.sub.peak=117° C. and ΔE=-15 J/g, and the second event at T.sub.onset=218° C., T.sub.peak=228° C. and ΔE=-39 J/g. Both endothermic events are linked to a mass loss, of 4% and 13%, respectively. TGR-IR analysis shows these mass losses to be primarily ethyl acetate and water, indicating that an ethyl acetate solvate has formed. Analysis of the HPLC data shows a purity of 94% purity for this solvate. FT-IR analysis confirms the chemical structure. Dynamic vapor sorption (DVS) analysis shows some stepwise sorption; the total mass uptake at 95 RH % is 5%. This salt is thus moderately hygroscopic.

(46) TABLE-US-00005 TABLE 2 Analytical results scale-up synthesis of the hydrochloride salt Polymorph 1 DVS DVS: Hygro- Mass HPLC scopicity DSC loss purity Solvent Appearance (%) (T.sub.peak ° C.) (%) (area %) Ethyl Yellow/brown 5 117 4 94 acetate solid 228 13

Example 3: Hydrochloride Crystal Salt Polymorph 2

(47) Approximately one gram of ITI-007 free base is added to toluene solvent at a concentration of 100 mg/mL. Hydrochloric acid in CPME solution is added to provide a 1:1 molar ratio of ITI-007

free base to HCl. The mixture is slurried at 50° C. overnight. The mixture is allowed to cool down to room temperature and is filtered and dried to give a yellow/brown solid. XRPD analysis shows the hydrochloride to be a crystalline solid. The XRPD pattern is shown in FIG. 2; the peaks are identified in tabular form in table 3:

(48) TABLE-US-00006 TABLE 3 XRPD peak list hydrochloride salt polymorph 2 # Angle d Value Rel. Intensity 1 10.51587 8.405758 0.510923 2 11.72088 7.54414 0.189459 3 12.09875 7.309357 0.796857 4 13.11974 6.74274 0.311634 5 14.24802 6.21123 0.24302 6 16.03021 5.524469 0.999989 7 16.56551 5.347139 0.83136 8 16.6931 5.306556 0.7834 9 18.93689 4.682549 0.251913 10 19.84092 4.471187 0.162883 11 21.09046 4.209022 0.703611 12 20.84009 4.25902 0.269821 13 21.77743 4.077775 0.750891 14 22.29105 3.984963 1 15 22.46965 3.953692 0.838087 16 24.20198 3.674474 0.667304 17 24.61919 3.61314 0.846243 18 26.8244 3.320902 0.36495 19 28.28183 3.152993 0.182531

(49) The hydrochloride salt is analyzed by DVS, DSC/TGA and HPLC, and the results are summarized in table 4. DSC/TGA analysis shows two endothermic events, the first at T.sub.onset=108° C., T.sub.peak=121° C. and $\Delta E=-23$ J/g, and the second at T.sub.onset=215° C., T.sub.peak=228° C. and $\Delta E=-57$ J/g. Both endothermic events are linked to a mass loss, of 4% and 13%, respectively. TGR-IR analysis shows these mass losses to be primarily toluene and water, indicating that a toluene solvate has formed. Analysis of the HPLC data shows a purity of 90% purity for this solvate. FT-IR analysis confirms the chemical structure. Dynamic vapor sorption (DVS) analysis shows some stepwise sorption; the total mass uptake at 95 RH % is 12%. This salt is thus moderately hygroscopic.

(50) TABLE-US-00007 TABLE 4 Analytical results scale-up synthesis of the hydrochloride salt polymorph 2 DVS Mass HPLC Hygroscopicity DSC loss purity Solvent Appearance (%)

(T.sub.peak ° C.) (%) (area %) Toluene Yellow/brown 12 121 4 90 solid 228 13

Example 4: Hydrochloride Crystal Salt Polymorph 3

(51) Approximately one gram of ITI-007 free base is added to CPME solvent at a concentration of 100 mg/mL. Hydrochloric acid in CPME solution is added to provide a 1:1 molar ratio of ITI-007 free base to HCl. The mixture is slurried at 50° C. overnight. The mixture is allowed to cool down to room temperature and is filtered and dried to give an off-white powdery solid. XRPD analysis shows the hydrochloride to be a crystalline solid. The XRPD pattern is shown in FIG. 3; the peaks are identified in tabular form in table 5:

(52) TABLE-US-00008 TABLE 5 XRPD peak list of the cyclamate salt # Angle d Value Rel. Intensity 1 6.113585 14.44517 0.204101 2 10.09204 8.757802 0.489434 3 10.35476 8.536179 0.605859 4 11.54239 7.660397 0.585963 5 12.08467 7.317844 1 6 12.93047 6.841012 0.161332 7 13.23207 6.685754 0.254659 8 15.77195 5.614344 0.712069 9 18.19631 4.871422 0.250223 10 19.51964 4.544048 0.326853 11 20.92257 4.242415 0.744994 12 23.86984 3.724845 0.732022 13 24.96878 3.563339 0.326213 14 26.39552 3.373879 0.575626

(53) The hydrochloride salt is analyzed by DVS, DSC/TGA and HPLC. The results are summarized in table 6. DSC/TGA analysis shows two endothermic events, the first at T.sub.onset=97° C., T.sub.peak=122° C. and $\Delta E=-38$ J/g, and the second event at T.sub.onset=192° C., T.sub.peak=209° C. and $\Delta E=-13$ J/g. Both endothermic events are linked to a mass loss, of 7% and 13%, respectively. TGR-IR analysis shows these mass losses to be primarily CPME and water, indicating that a CPME solvate has formed. Analysis of the HPLC data shows a purity of 80% purity for this solvate. FT-IR analysis confirms the chemical structure. Dynamic vapor sorption (DVS) analysis shows some stepwise sorption; the total mass uptake at 95 RH % is 10%. This salt is thus moderately hygroscopic.

(54) TABLE-US-00009 TABLE 6 Analytical results scale-up synthesis of the hydrochloride salt Polymorph 3. DVS Hygro- Mass HPLC scopicity DSC loss purity Solvent Appearance (%)

(T.sub.peak ° C.) (%) (area %) CPME Off-White 10 122 7 80 powder 209 13

Example 5: Competitive Stability Test of Hydrochloride Crystal Salt Polymorphs

(55) To determine the most stable of the three hydrochloride crystal salt polymorphs, a competitive slurry in 1-butanol is performed. Equal masses of the three polymorphs obtained according to Examples 2-4 above are mixed and slurried at room temperature and at 50° C. for 24 hours. XRPD analysis is then performed. Both slurry conditions result in a new crystalline pattern, suggesting the formation of a new solvate form. The XRPD spectra are shown in FIG. 4 (top: 50° C.; bottom: RT). DSC/TGA analysis shows two endothermic events, the first at T.sub.onset=142° C., T.sub.peak=150° C. and $\Delta E=-14$ J/g, and the second event at T.sub.onset=203° C., T.sub.peak=216° C. and $\Delta E=-17$ J/g. The TGA profiles shows three mass losses. The first two of 6% and 8% correspond, respectively, to the two endothermic events. TGR-IR analysis shows the first two of these mass losses to be primarily 1-butanol and water, indicating that a 1-butanol solvate has formed. The third mass loss occurs above 240° C. and likely corresponds to decomposition.

Claims

1. A method for the treatment of a human suffering from a disease or abnormal condition involving or mediated by the 5-HT_{2A} receptor, serotonin transporter (SERT), and/or dopamine D₁/D₂ receptor signaling pathways comprising administering to said human an effective amount of hydrochloride salt of 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido [3',4': 4,5]pyrrolo [1,2,3-de]quinoxalin-8-yl)-butan-1-one, wherein the salt is in crystalline form and wherein the crystalline form is selected from the group consisting of: (a) polymorph 1 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 7.29, 10.28, 10.44, 12.21, 13.42, 15.24, 16.29, 16.81, 18.82, 19.57, 21.14, 22.06, 22.07, 22.63, 23.78, 24.31, 25.03, 26.40, 26.44, 26.50, 27.24, 29.36, and 33.53, and/or at least five d-spacing values selected from the group consisting of 12.12, 8.60, 8.47, 7.24, 6.59, 5.81, 5.44, 5.27, 4.71, 4.53, 4.20, 4.03, 4.02, 3.93, 3.74, 3.66, 3.56, 3.37, 3.37, 3.36, 3.27, 3.04, and 2.67; (b) polymorph 2 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 10.52, 11.72, 12.10, 13.12, 14.25, 16.03, 16.57, 16.69, 18.94, 19.84, 21.09, 20.84, 21.78, 22.29, 22.47, 23.20, 24.62, 26.82, and 28.28, and/or d-spacing values selected from the group consisting of 8.41, 7.54, 7.31, 6.74, 6.21, 5.52, 5.35, 5.31, 4.68, 4.47, 4.21, 4.26, 4.08, 3.98, 3.95, 3.67, 3.61, 3.32, and 3.15; and (c) polymorph 3 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 6.11, 10.09, 10.35, 11.54, 12.08, 12.93, 13.23, 15.77, 18.20, 19.52, 20.92, 23.87, 24.97, and 26.40, and/or d-spacing values selected from the group consisting of 14.45, 8.76, 8.54, 7.66, 7.32, 6.84, 6.69, 5.61, 4.87, 4.54, 4.24, 3.73, 3.56, and 3.37; and wherein the disease or condition is selected from depression, anxiety, psychosis, schizophrenia, social phobias, and dementia.

2. The method according to claim 1, wherein the patient is administered a pharmaceutical composition comprising the hydrochloride salt of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido [3',4': 4,5]pyrrolo [1,2,3-de]quinoxalin-8-yl)-butan-1-one, in combination or association with a pharmaceutically acceptable diluent or carrier.

3. The method according to claim 1, wherein the disease or condition is selected from depression, anxiety, psychosis, and schizophrenia.

4. The method according to claim 3, wherein the disease or condition is selected from depression, anxiety, and schizophrenia.

5. The method according to claim 4, wherein the disease or condition is schizophrenia.

6. The method according to claim 1, wherein the crystalline form of the hydrochloride salt is the salt characterized as polymorph 1 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 7.29, 10.28, 10.44, 12.21, 13.42, 15.24, 16.29, 16.81, 18.82, 19.57, 21.14, 22.06, 22.07, 22.63, 23.78, 24.31, 25.03, 26.40, 26.44, 26.50, 27.24,

29.36, and 33.53, and/or at least five d-spacing values selected from the group consisting of 12.12, 8.60, 8.47, 7.24, 6.59, 5.81, 5.44, 5.27, 4.71, 4.53, 4.20, 4.03, 4.02, 3.93, 3.74, 3.66, 3.56, 3.37, 3.37, 3.36, 3.27, 3.04, and 2.67.

7. The method according to claim 1, wherein the crystalline form of the hydrochloride salt is the salt characterized as polymorph 2 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 10.52, 11.72, 12.10, 13.12, 14.25, 16.03, 16.57, 16.69, 18.94, 19.84, 21.09, 20.84, 21.78, 22.29, 22.47, 23.20, 24.62, 26.82, and 28.28, and/or d-spacing values selected from the group consisting of 8.41, 7.54, 7.31, 6.74, 6.21, 5.52, 5.35, 5.31, 4.68, 4.47, 4.21, 4.26, 4.08, 3.98, 3.95, 3.67, 3.61, 3.32, and 3.15.

8. The method according to claim 1, wherein the crystalline form of the hydrochloride salt is the salt characterized as polymorph 3 having an X-ray diffraction pattern having at least five angle (2-theta) values selected from the group consisting of 6.11, 10.09, 10.35, 11.54, 12.08, 12.93, 13.23, 15.77, 18.20, 19.52, 20.92, 23.87, 24.97, and 26.40, and/or d-spacing values selected from the group consisting of 14.45, 8.76, 8.54, 7.66, 7.32, 6.84, 6.69, 5.61, 4.87, 4.54, 4.24, 3.73, 3.56, and 3.37.
